Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. [electronic resource]
Producer: 19980618Description: 1664-73 p. digitalISSN:- 0022-1899
- Adolescent
- Adult
- Amino Acid Sequence
- Antibodies, Protozoan -- immunology
- Antigens, Protozoan -- adverse effects
- Consumer Product Safety
- Female
- Genetic Vectors
- Humans
- Malaria Vaccines -- adverse effects
- Male
- Middle Aged
- Molecular Sequence Data
- T-Lymphocytes, Cytotoxic -- immunology
- Vaccines, Attenuated -- adverse effects
- Vaccines, Synthetic -- adverse effects
- Vaccinia virus
- Viral Proteins -- adverse effects
- Viral Vaccines -- adverse effects
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.